{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:40:51Z","timestamp":1793320851835,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,25]],"date-time":"2027-07-25T00:00:00Z","timestamp":1816473600000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.104860","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:22:21Z","timestamp":1783351341000},"page":"104860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cadonilimab for recurrent small cell neuroendocrine carcinoma of the cervix: a phase 2 study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-4001","authenticated-orcid":false,"given":"Helen D.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-4151","authenticated-orcid":false,"given":"Michael","family":"Frumovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7035-0727","authenticated-orcid":false,"given":"Kelly M.","family":"Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8058-8435","authenticated-orcid":false,"given":"Zhouxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":false,"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-7463","authenticated-orcid":false,"given":"Larissa A.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-0795","authenticated-orcid":false,"given":"Travis T.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ijgc.2026.104860_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102011","article-title":"Clinical and pathological characteristics and outcomes of small cell neuroendocrine carcinoma of the uterine cervix","volume":"35","author":"Kobayashi","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104860_bib2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104860_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ygyno.2008.11.010","article-title":"Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy","volume":"112","author":"Zivanovic","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104860_bib4","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/AOG.0b013e318173570b","article-title":"Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix","volume":"111","author":"Chen","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104860_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2011.04.011","article-title":"Neuroendocrine tumors of the gynecologic tract: a society of Gynecologic Oncology (SGO) clinical document","volume":"122","author":"Gardner","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104860_bib6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ygyno.2020.05.682","article-title":"Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract","volume":"158","author":"Frumovitz","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104860_bib7","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104860_bib8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104860_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104860_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104860_bib11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1470-2045(24)00088-3","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1\u20132, open-label, multicohort trial","volume":"25","author":"Oaknin","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104860_bib12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10421","key":"10.1016\/j.ijgc.2026.104860_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"10463","key":"10.1016\/j.ijgc.2026.104860_bib14","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104860_bib15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:45:28Z","timestamp":1788813928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26003919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1048891X26003919"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104860","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cadonilimab for recurrent small cell neuroendocrine carcinoma of the cervix: a phase 2 study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104860"}}